John Klein - Guiding Cambridge Therapeutics in New Jersey

Posts

Costs Associated with Enterprise Performance Management

An award-winning pharmaceutical executive based in Alpine, New Jersey, John Klein founded Cambridge Therapeutics and Bi-Logix, LLC, in 2011 and 2015, respectively (both located in Alpine, NJ). Bi-Logix, LLC, is an enterprise performance management (EPM) firm that helps companies obtain sustainable measured performance via its proprietary business solutions and methodology, which is copyrighted by John Klein. EPM solutions help businesses improve their IT infrastructure and increase overall corporate efficiency, which, in turn, helps them cut costs and increase revenue. While there are costs associated with EPM implementation, its long-term benefits significantly outweigh the impact of short-term spending. In addition to paying for EPM software licensing and maintenance, businesses might also have to budget costs for database software to help run the EPM. Other costs that might be accrued include the maintenance and upgrading of hardware, as well as fees for third-party inte

Overview of the EPM Solution Chain

In 2011, John Klein founded Cambridge Therapeutics in Alpine, New Jersey, where he currently serves as chairman. Four years later, John Klein expanded his professional endeavors beyond Cambridge Therapeutics by founding Bilogix, LLC, an enterprise performance management (EPM) services provider also based in Alpine, NJ. The EPM solution chain consists of five key points that can be optimized to address the needs of specific industries and vendors. Strategy and metrics visualization is the first step in the EPM solution chain and involves a number of strategy maps and business activity monitoring processes, along with the scorecards and dashboards often associated with EPM support. Enterprise planning and budgeting, meanwhile, can be described as the strategic integration of budgeting and forecasting applications with tactical enterprise planning efforts. Financial modeling and analysis is another important part of the EPM solution chain and can be achieved through a range of proce

Bilogix Implements Enterprise Performance Management Solutions

The chairman of Alpine, New Jersey-based Cambridge Therapeutics, John Klein offers next-generation solutions in areas ranging from combination therapies to drug delivery. Building on his experience with Cambridge Therapeutics, John Klein recently launched Bilogix in Alpine, NJ, a provider of enterprise performance management (EPM) consulting services. Encompassing processes and applications, the EPM approach is one that transforms key performance indicator (KPI) data into highly accurate ways of analyzing, monitoring, measuring, and forecasting organizational results. It adds value through bringing focus on the details of how strategic plans are envisioned and implemented, as well as how challenges and inconsistencies are addressed when they occur. This ensures that resources are utilized more efficiently toward defined goals, at both the operational and tactical levels. At the same time, the effects of business intelligence investments can be tracked via a dashboard and r

EPM Application Market 2023 Forecast

Technavio logo image: technavio.com A former Mitchell & Co. Outstanding CEO honoree, John Klein serves as chairman of Cambridge Therapeutics, which he founded in 2011 to deliver combination drug therapies. Concurrently, John Klein is the chairman and CEO of the Alpine, NJ-based Bilogix, LLC, through which he provides enterprise performance management (EPM) solutions to business clients to better inform their decision-making processes and improve operational performance. According to Technavio , the EPM application market is expected to grow by more than $2 billion by 2023, which equates to a compound annual growth rate of nearly 9 percent. Technavio has been monitoring the global market since 2015 and presented its findings in its recent 132-page market analysis report. The report states that market growth will be driven by demand for cloud-based EPM solutions in addition to companies seeking to satisfy changing regulations. Given the volume and sensitive nature of data trans

NJ Attorney General Reveals Measures to Combat Opioid Epidemic

The chairman of Cambridge Therapeutics in Teaneck, New Jersey, John Klein has obtained FDA approval for more than 300 generic drugs in the course of his 30-year career. His work at Cambridge Therapeutics has resulted in honors including high ranking on Forbes’ list of the Top 100 CEOs. Complementing that work, John Klein closely follows health and related developments in New Jersey. The state’s attorney general, Gurbir Grewal, recently announced new efforts aimed at battling the state’s opioid epidemic. Grewal has proposed a rule change to make medication-assisted treatment, long recognized as the most effective way to treat opioid addiction, more widely available to the state’s residents through use of telemedicine technology. Allowing physicians to assess and prescribe treatments to patients through two-way, real-time video communication will ensure more people can access medication-assisted treatment and improve their odds of surviving their opioid addiction. In addition, Grewa

New Jersey Aims to Ensure That All Children Have Health Insurance

John Klein has led Teaneck, New Jersey-based Cambridge Therapeutics since founding the pharmaceutical products manufacturer nearly a decade ago. He and his company provide a range of customer-friendly medical packaging options designed to increase patient adherence to prescription regimens. In addition to his role with Cambridge Therapeutics, John Klein is a board member with Hackensack Meridian Health Hospitals and regularly studies emerging information in the healthcare field in his state. In order to care for the most vulnerable of its citizens, the state of New Jersey oversees NJFamilyCare , a publicly funded insurance program that offers free or affordable health insurance for individuals of all ages. The program entitles policy holders to obtain visits to physicians, dentists, mental health professionals, and vision care specialists, as well as hospital services. However, the research group New Jersey Policy Perspective noted that the number of children enrolled in NJFamilyCar